#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15274	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2136	711.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1456	1456	C	853	C,T	798,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15274	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2136	711.9	0	HET	.	.	.	A69G	.	69	69	A	341	341	A	859	A,G	611,196	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28346	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3498	807.6	0	.	n	.	0	T695C	SNP	695	695	T	999	999	C	932	C,T	842,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28346	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3498	807.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1641	1641	A	936	A,T	861,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28346	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3498	807.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2275	2275	C	875	C,T	802,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28346	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3498	807.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2349	2349	A	918	A	854	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28346	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3498	807.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2901	2901	C	865	C	815	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2036	folP	855	855	100.0	folP.l15.c30.ctg.1	1658	122.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1087	1089	AGC	206;205;207	A;G;C	191;190;191	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5642	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3286	170.9	1	SNP	p	S91F	1	.	.	271	273	TTC	491	493	TTC	172;173;176	T;T,C;C	159;158,1;161	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5642	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3286	170.9	1	SNP	p	G95N	0	.	.	283	285	GGC	503	505	GGC	171;170;171	G;G,C,A;C	155;152,1,1;155	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5642	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3286	170.9	1	SNP	p	D95G	1	.	.	283	285	GGC	503	505	GGC	171;170;171	G;G,C,A;C	155;152,1,1;155	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1672	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1342	124.2	1	SNP	p	G45D	0	.	.	133	135	GGC	448	450	GGC	204;203;205	G;G;C	186;182;183	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	864	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1016	84.7	0	.	n	.	0	A197.	DEL	197	197	A	619	619	A	209	A	198	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2846	186.6	1	SNP	p	D86N	0	.	.	256	258	GAC	518	520	GAC	227;228;227	G;A;C	212;207;210	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2846	186.6	1	SNP	p	S87R	1	.	.	259	261	CGT	521	523	CGT	226;227;230	C;G;T	209;212;211	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2846	186.6	1	SNP	p	R87I	0	.	.	259	261	CGT	521	523	CGT	226;227;230	C;G;T	209;212;211	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2846	186.6	1	SNP	p	R87W	0	.	.	259	261	CGT	521	523	CGT	226;227;230	C;G;T	209;212;211	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2846	186.6	1	SNP	p	S88P	0	.	.	262	264	TCC	524	526	TCC	230;229;227	T;C;C	210;210;209	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4478	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2843	157.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1629	1631	GGC	241;238;237	G;G;C	221;220;218	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1322	1324	GCA	236;236;243	G;C;A	215;214;225	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1325	1327	ATC	243;244;246	A;T;C	225;226;229	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1337	1339	GTG	239;238;238	G;T;G	222;220;218	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1337	1339	GTG	239;238;238	G;T;G	222;220;218	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1841	1843	ACC	192;192;192	A;C;C	173;174;177	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1895	1897	GCG	179;179;182	G;C;G	154;141;143	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1895	1897	GCG	179;179;182	G;C;G	154;141;143	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2018	2020	AGC	167;167;166	A,G;G;C	148,1;148;148	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2027	2029	GGC	170;170;169	G;G;C	152;150;153	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4122	penA	1752	1752	100.0	penA.l15.c30.ctg.1	2452	167.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2045	2047	CCG	140;145;146	C,G;C,T,G;G	94,5;97,1,2;102	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5726	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3080	185.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1619	1621	CCG	197;198;196	C;C;G	173;183;176	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2304	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1762	130.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	559	559	C	161	C	147	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	495	497	CAG	228;227;224	C;A,C;G	214;214,1;211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	519	521	GGA	248;248;250	G;G;A	228;229;230	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	F135L	NONSYN	403	405	TTT	780	782	CTT	224;224;224	C,T;T;T	211,1;212;210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	804	806	GGA	231;230;229	G,A;G;A	212,1;213;209	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	G189S	NONSYN	565	567	GGC	942	944	AGC	217;213;214	A;G;C	200;198;195	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	Y211_N212insDGQ	INS	631	631	T	1008	1008	T	237	T	228	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	N212_S213insL	INS	634	634	A	1021	1021	C	237	C	228	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	I214M	NONSYN	640	642	ATC	1029	1031	ATG	241;239;239	A;T;G	226;226;226	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	L218F	NONSYN	652	654	CTT	1041	1043	TTT	247;247;247	T;T;T	235;235;233	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	A238V	NONSYN	712	714	GCC	1101	1103	GTT	208;209;207	G;T;T	195;195;194	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	T252A	NONSYN	754	756	ACA	1143	1145	GCA	206;210;211	G;C;A	191;194;196	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	W253T	NONSYN	757	759	TGG	1146	1148	ACG	213;215;220	A;C;G	197;200;205	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	S254R	NONSYN	760	762	AGT	1149	1151	AGG	222;223;225	A;G;G	204;207;207	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	A255V	NONSYN	763	765	GCT	1152	1154	GTT	224;222;223	G;T,A;T	207;206,1;211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1212	1214	GTA	259;258;255	G;T;A	238;235;234	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1251	1253	ACT	257;260;260	A;C,T;T	228;232,1;231	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1257	1259	GAT	260;260;260	G;A,T;T	230;229,1;232	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1260	1262	GAT	257;257;257	G;A,T;T	224;225,1;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1266	1268	AAC	256;257;259	A;A;C	227;229;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1269	1271	CAC	257;258;258	C;A;C	229;231;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1374	1376	GAC	245;244;242	G;A;C	233;230;231	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	1	SNP	p	G120K	0	.	.	358	360	GGT	735	737	GGT	206;209;211	G;G;T,C	193;197;193,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	1	SNP	p	A121D	0	.	.	361	363	GCC	738	740	GCC	207;208;209	G;C;C	195;197;197	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2808	porB1b	1035	1035	96.37	porB1b.l15.c30.ctg.1	1579	177.5	1	SNP	p	A121N	0	.	.	361	363	GCC	738	740	GCC	207;208;209	G;C;C	195;197;197	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11024	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4832	227.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1274	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	932	134.8	1	SNP	p	V57M	1	.	.	169	171	ATG	512	514	ATG	245;246;245	A;T;G	233;232;235	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
